Biopharmaceutical company Retrotope survived an effort by dissident shareholders to toss its Chapter 11 case after a judge said the bankruptcy wasn’t filed in bad faith after receiving proper consideration from the company’s board.
A motion by three Retrotope shareholders to dismiss the Chapter 11 filing was rejected at a Thursday hearing by Judge John T. Dorsey of the U.S. Bankruptcy Court for the District of Delaware.
The ruling represents a win for the Retrotope amid an ongoing disagreement between some shareholders and management over the company’s direction after failed trials for one of its drugs.
Retrotope, which develops drugs ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.